To the Editor: Small cell lung cancer (SCLC) transformation is one of the most common mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-SCLC (NSCLC). However, whether such transformation is one from NSCLC to SCLC or the coexistence of both remains controversial.\[[@ref1]\] In this study, we performed next-generation sequencing (NGS) with a panel of 168 tumor genes for consecutive repeat biopsy tissue samples of a lung adenocarcinoma patient harboring *EGFR* exon 19 deletion (ex19del).

In a nonsmoking 26-year-old female patient with chest pain, computed tomography (CT) scan revealed a right lung mass and pleural effusion. Positron emission tomography CT demonstrated right pleura metastases. Cell mass from pleural effusion (Sample A) revealed metastatic lung adenocarcinoma, positive for *EGFR* ex19del. The patient received gefitinib, with partial response as best response. Four months later, CT scan demonstrated disease progression with increasing pleural effusion and lung nodules. A CT-guided percutaneous transthoracic needle biopsy (PTNB) was performed (Sample B), showing a combined tumor presenting adenocarcinoma and SCLC features with the original *EGFR* ex19del. The patient was treated with gefitinib combined with five cycles of chemotherapy of cisplatin and etoposide. After partial response for 3 months, the mass was found to progress again. Repeat PTNB (Sample C) revealed pure SCLC (*EGFR* ex19del). To further explore the cause of rapid progress, we examined Sample C with fluorescence *in situ* hybridization, finding no anaplastic lymphoma kinase fusion or c-MET amplification. Ten milliliter of blood was collected for the cell-free DNA (cfDNA) analysis. Meanwhile, Sample A, Sample B, Sample C, and blood sample were tested by targeted NGS with a panel of 168 tumor genes. The result showed that Sample A, B, C, and blood sample all held *TP53* C176S and *EGFR* ex19del; the allele frequency of *TP53* C176S and *EGFR* ex19del was 9.1% and 12.7% in Sample A, 87.3% and 86.6% in Sample B, 97.2% and 98.4% in Sample C, and 78.0% and 74.7% in blood sample, respectively; the mutations in chromosomes were always present at the same sites. Unfortunately, the patient died soon. The patient\'s timeline of therapies and diagnostic procedures is shown in [Figure 1](#F1){ref-type="fig"}.

![The patient\'s timeline of therapies and diagnostic procedures. (a) Chest positron emission tomography CT; (b-d) chest CT; (e and f) timeline of treatment; (g-i) pathological pictures of Sample A, B, C; Sample A and C: HE staining, Sample B: HE and immunohistochemistry staining. green, blue arrow: small cell lung cancer and adenocarcinoma in Sample B. AF: Allele frequency; EP: Etoposide cisplatin; EGFR: Epidermal growth factor receptor; EGFR-TKI: EGFR-tyrosine kinase inhibitor; TTF-1: Thyroid transcription factor-1; CT: Computed tomography; HE: Hematoxylin-eosin.](CMJ-131-1124-g001){#F1}

Our study confirmed repeat PTNB was the effective way to fully understand the mechanisms of resistance and to allow discrimination of tumors with SCLC transformation.\[[@ref2]\] The NGS results of consecutive repeat biopsy samples, which showed the presence of *TP53* C176S and *EGFR* ex19del and the same change trend shared by them, confirmed that SCLC transformation is one caused by a phenotypic switch that originates from the common cell type rather than intratumor heterogeneity. Such result is consistent with that of Mainardi *et al*.\[[@ref3]\] that alveolar Type II cells have the capacity to develop into adenocarcinoma. Besides, loss of *TP53* could efficiently transform alveolar Type II cells, leading to SCLC.\[[@ref4]\] In conclusion, NGS of repeat PTNB biopsy can be applied to monitor and overcome resistance to EGFR-TKI therapy.
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